BioCentury | Dec 20, 2010
Clinical News

GGF2: Phase I started

...I trial evaluating IV GGF2 in about 50 patients. Acorda gained rights to GGF2 from CeNes Pharmaceuticals plc...
BioCentury | May 31, 2010
Finance

Performance Counts

...II Desmoteplase Ph III [stroke] Specialty pharma: stroke, anticoagulants; added CNS after 2008 acquisition of CeNeS Pharmaceuticals plc...
BioCentury | Nov 10, 2008
Clinical News

M6G: Data

...of action and better side-effect profile than morphine. Paion gained M6G through its acquisition of CeNeS Pharmaceuticals plc...
BioCentury | Sep 22, 2008
Finance

Shaking in their shorts

...Wyatt joined Imperial Innovations , the U.K. tech transfer firm. Kerr was commercial director at CeNeS...
BioCentury | Aug 4, 2008
Clinical News

Acorda, Paion preclinical data

...has an exclusive, worldwide license to the growth factor to stimulate promotion of myelin from CeNes Pharmaceuticals plc...
BioCentury | Jul 14, 2008
Clinical News

CNS 7056: Phase I start

...40-90 healthy volunteers. The company acquired CNS 7056 earlier this year through its acquisition of CeNeS Pharmaceuticals plc...
BioCentury | Jul 7, 2008
Finance

Restructuring watch

...38% to 40 $76.8 10.11 3/31/08 $1.9 (A) Cuts come as a result of acquiring CeNeS...
BioCentury | Jun 30, 2008
Company News

CeNeS, Paion deal

...Paion completed its previously announced acquisition of CeNeS for about 7.9 million shares, or €11.1 million...
...June 20, the last day of trading before the deal closed (see BioCentury, April 14). CeNeS Pharmaceuticals plc...
BioCentury | Jun 16, 2008
Finance

Ebb & Flow

...is planning to get a secondary listing on London's AIM market following its acquisition of CeNeS...
...The company is maintaining an AIM listing partly because tax rules restrict a number of CeNeS's...
...attract the attention of both sellside analysts and investors. The last day of dealing in CeNeS...
BioCentury | Jun 2, 2008
Company News

CeNeS, GlaxoSmithKline deal

...CeNeS will issue 120,752 shares to GlaxoSmithKline as part of a 2003 deal under which CeNeS...
...associated compounds from the pharma company. The payment is valued at £36,000 ($71,800) based on CeNeS’s...
...CNS 7056, a GABA A receptor modulator. GlaxoSmithKline has no further rights beyond this milestone. CeNeS...
Items per page:
1 - 10 of 211
BioCentury | Dec 20, 2010
Clinical News

GGF2: Phase I started

...I trial evaluating IV GGF2 in about 50 patients. Acorda gained rights to GGF2 from CeNes Pharmaceuticals plc...
BioCentury | May 31, 2010
Finance

Performance Counts

...II Desmoteplase Ph III [stroke] Specialty pharma: stroke, anticoagulants; added CNS after 2008 acquisition of CeNeS Pharmaceuticals plc...
BioCentury | Nov 10, 2008
Clinical News

M6G: Data

...of action and better side-effect profile than morphine. Paion gained M6G through its acquisition of CeNeS Pharmaceuticals plc...
BioCentury | Sep 22, 2008
Finance

Shaking in their shorts

...Wyatt joined Imperial Innovations , the U.K. tech transfer firm. Kerr was commercial director at CeNeS...
BioCentury | Aug 4, 2008
Clinical News

Acorda, Paion preclinical data

...has an exclusive, worldwide license to the growth factor to stimulate promotion of myelin from CeNes Pharmaceuticals plc...
BioCentury | Jul 14, 2008
Clinical News

CNS 7056: Phase I start

...40-90 healthy volunteers. The company acquired CNS 7056 earlier this year through its acquisition of CeNeS Pharmaceuticals plc...
BioCentury | Jul 7, 2008
Finance

Restructuring watch

...38% to 40 $76.8 10.11 3/31/08 $1.9 (A) Cuts come as a result of acquiring CeNeS...
BioCentury | Jun 30, 2008
Company News

CeNeS, Paion deal

...Paion completed its previously announced acquisition of CeNeS for about 7.9 million shares, or €11.1 million...
...June 20, the last day of trading before the deal closed (see BioCentury, April 14). CeNeS Pharmaceuticals plc...
BioCentury | Jun 16, 2008
Finance

Ebb & Flow

...is planning to get a secondary listing on London's AIM market following its acquisition of CeNeS...
...The company is maintaining an AIM listing partly because tax rules restrict a number of CeNeS's...
...attract the attention of both sellside analysts and investors. The last day of dealing in CeNeS...
BioCentury | Jun 2, 2008
Company News

CeNeS, GlaxoSmithKline deal

...CeNeS will issue 120,752 shares to GlaxoSmithKline as part of a 2003 deal under which CeNeS...
...associated compounds from the pharma company. The payment is valued at £36,000 ($71,800) based on CeNeS’s...
...CNS 7056, a GABA A receptor modulator. GlaxoSmithKline has no further rights beyond this milestone. CeNeS...
Items per page:
1 - 10 of 211